1. Home
  2. TCBK vs ANAB Comparison

TCBK vs ANAB Comparison

Compare TCBK & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriCo Bancshares

TCBK

TriCo Bancshares

HOLD

Current Price

$53.52

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$67.79

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCBK
ANAB
Founded
1975
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
TCBK
ANAB
Price
$53.52
$67.79
Analyst Decision
Buy
Buy
Analyst Count
5
12
Target Price
$54.60
$71.67
AVG Volume (30 Days)
159.4K
535.2K
Earning Date
04-23-2026
05-08-2026
Dividend Yield
2.87%
N/A
EPS Growth
6.94
91.02
EPS
1.04
N/A
Revenue
$53,445,000.00
$234,603,000.00
Revenue This Year
$12.03
N/A
Revenue Next Year
$4.47
$52.14
P/E Ratio
$51.20
N/A
Revenue Growth
4.12
157.01
52 Week Low
$39.84
$17.11
52 Week High
$54.17
$73.30

Technical Indicators

Market Signals
Indicator
TCBK
ANAB
Relative Strength Index (RSI) 61.79 68.62
Support Level $48.57 $52.32
Resistance Level N/A $67.69
Average True Range (ATR) 1.04 3.32
MACD 0.17 1.47
Stochastic Oscillator 82.12 87.83

Price Performance

Historical Comparison
TCBK
ANAB

About TCBK TriCo Bancshares

TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: